Skip to main content
OCGN logo

OCGN · Ocugen, Inc.

Track OCGN — free
$1.35 +0.00 (+0.00%) At close · Aug 14
Market Cap
$457.80M
Shares
339.11M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.35 Open$1.36 Day$1.31–1.36 52W close$1.00–2.48 Avg vol 30d4.7M Short int100.9M · 29.8% float · 21.6d Short vol51% Last earningsAug 6, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Nov 9, 2026 Est · unconfirmed · in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Aug 6, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Buy Momentum Weak Sentiment Bullish Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg −11%
      below
      Price vs 50-day avg +1%
      above
      RSI (14) 52
      neutral
      MACD trend Positive
      52-week position 24%
      mid-range
      Momentum
      relative strength
      Weak
      1-month return −1%
      trailing
      6-month return −18%
      trailing
      YTD return 0%
      this year
      Relative strength −31%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $1 › 200d $2 — 200d above 50d
      Institutional flow Accumulating
      +9% holders QoQ · +44 funds added
      Insider flow Accumulating
      Net +$25.8K over 90 days · 0% sells
      Short interest Rising
      29.76% of float · ▲ +0.3% MoM · 21.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      149 holders — near 3-yr high, broad support
      Squeeze score 76
      high risk · 0–100
      Fundamentals
      Weak
      Revenue growth −100%
      Y/Y
      EPS growth +35%
      Y/Y
      Free cash flow $-57.1M
      Balance sheet $10.2M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 80%
      annualized · 1-yr
      Max drawdown −52%
      past year
      ATR 5.5%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 3 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −11% Bearish
      Price vs 50-day avg
      +1% Bullish
      RSI (14)
      52 Neutral
      MACD trend
      Positive Bullish
      52-week position
      24% Neutral
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $1 › 200d $2 — 200d above 50d
      Institutional flow Accumulating
      +9% holders QoQ · +44 funds added
      Insider flow Accumulating
      Net +$25.8K over 90 days · 0% sells
      Short interest Rising
      29.76% of float · ▲ +0.3% MoM · 21.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      149 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $1 Now $1 · 24% Range high $2
      vs 200-day avg -11% vs 50-day avg +1%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      shares of common stock outstanding 339M Q2 2026

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      OCGN
      Ocugen, Inc.
      this stock
      $457.80M +0.0% -100.0% 29.8%
      ONC
      BeOne Medicines Ltd.
      $513.62B +14.4% +22179.2% 789.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      $128.19B +11.6% +46.2% 29.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      $82.72B +4.1% +20.8% 19.9 3.3%
      ARGX
      Argenx SE
      $52.94B +1.2% 2.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      149
      % held
      43.6%
      Net QoQ
      +34.1M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      40
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      100.9M
      Days to cover
      21.6d
      Change
      +323.2K sh
      View
      Short Volume
      Short vol %
      51%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      189.4K
      Value
      $267.0K
      As of
      Jul 14, 2026
      View
      Off-Exchange
      Off-exchange %
      44.3%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net buying
      Net (90d)
      +$25.8K
      Buyers / Sellers
      1 / 0
      Buyers Sellers
      View
      Congressional Trades Sell
      Member
      Christopher L. Jacobs
      Amount
      $1.0K–$15.0K
      Traded
      Nov 8, 2022
      View
      Financials
      Financials
      Revenue (FY)
      $4.4M
      Net income (FY)
      $-68.0M
      EPS diluted
      $-0.26
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 6, 2026
      This year
      24
      View
      Proposed Sales
      Value
      $122.9K
      Shares
      112.2K
      Filed
      Jul 9, 2025
      View
      Exempt Offerings
      Offering
      $395
      Filed
      May 7, 2020
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 6, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      OCGN +5.5% -0.7% -17.7% +9.8% +0.0%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY +5.1% -5.2% -31.5% +5.8% -13.9%
      Key facts CIK 1372299 CUSIP 67577C105 13F (30d) 143 filings 141 filers Visit website Investor relations